The North Bay Business Journal1d
Swiss drugmaker finalizes sale of Genentech biomed campus in Vacaville
Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...
Genenexer who sold two startups for $1 billion each named CEO of CuraSen Therapeutics
Glaub and Ford worked together at Afferent Pharmaceuticals Inc., where Glaub was CEO and Ford chief scientific officer. Their ...
STAT2d
Jasper, looking to rival Genentech and Novartis’ Xolair, reports positive data for skin condition drug
Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...
GlobalData on MSN2d
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial
Data from the Rainbowfish trial was presented at the World Muscle Society (WMS) Congress 2024 in Prague, Czech Republic.
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
FDA approves Genentech drug aimed at subset of breast cancer patients
The potential blockbuster drug was approved by the agency more than a month before its scheduled decision date. A potential ...
The Pharma Letter6d
FDA approves Genentech’s Itovebi for PIK3CA-mutated mBC
The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...
BioWorld5d
FDA gives early nod to Genentech’s first-line breast cancer drug
Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...
BioSpace1d
Jasper Posts Promising Mid-Stage Data for Urticaria Drug, Eyes Challenge to Blockbusters
With positive results for patients with the chronic skin condition, Jasper Therapeutics’ briquilimab is looking to take on ...
Week In Review: Regor Sells 2 CDK Inhibitors To Genentech For $850m
Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast ...
Roche/Genentech’s Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results
While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious complication of systemic lupus ...
Business Wire6d
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Itovebiâ„¢ (inavolisib), in ...